Tarveda Therapeutics, Inc., formerly Blend Therapeutics, today announced that it has secured $38 million in Series C financing co-led by new investor Novo A/S and existing investor New Enterprise Associates (NEA). The company also announced the change of its corporate brand to clearly highlight the company’s differentiated approach to treating cancer.
{iframe}http://www.businesswire.com/news/home/20160127005371/en/Blend-Therapeutics-Secures-38-Million-Series-Financing{/iframe}